×
About 455 results

ALLMedicine™ POEMS Syndrome Center

Research & Reviews  174 results

Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome
https://clinicaltrials.gov/ct2/show/NCT02921893

May 13th, 2022 - PRIMARY OBJECTIVE: I. Normalization of VEGF after 3 cycles of therapy. SECONDARY OBJECTIVES: I. Toxicity and safety of the combination of ixazomib citrate (ixazomib), lenalidomide, and dexamethasone. II. Hematologic response after 3 cycles of ther...

Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comp...
https://doi.org/10.1182/bloodadvances.2022007218
Blood Advances; Kansagra A, Dispenzieri A et. al.

May 5th, 2022 - Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma.|2022|Kansagra A,Dispenzieri A,Fraser R,Estrada-Merly N,Sidana S,|

POEMS Syndrome: Skin Lesions Bringing the Jigsaw Puzzle Together.
https://www.ncbi.nlm.nih.gov/pubmed/35435828
Skinmed Chhabra N, Sharma H et. al.

Apr 19th, 2022 - A 47-year-old man presented to the outpatient department with multiple asymptomatic, erythematous and violaceous, soft, dome-shaped papulonodular lesions that had been present for 3 years. The lesions were vascular and were about 1 cm in diameter....

Vitamin B6 deficiency as a cause of polyneuropathy in POEMS syndrome: rapid recovery wi...
https://doi.org/10.1080/16078454.2022.2060456
Hematology (Amsterdam, Netherlands); Yasuda H, Furukawa Y et. al.

Apr 13th, 2022 - The etiology of POEMS syndrome and its associated polyneuropathy have not been fully elucidated. The clinical picture of POEMS-associated polyneuropathy and nutritional polyneuropathy due to vitamin B6 (VB6) deficiency are strikingly similar, both...

Cutaneous manifestations of monoclonal gammopathy.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9001632
Blood Cancer Journal; Claveau JS, Wetter DA et. al.

Apr 13th, 2022 - Monoclonal gammopathy associated with dermatological manifestations are a well-recognized complication. These skin disorders can be associated with infiltration and proliferation of a malignant plasma cells or by a deposition of the monoclonal imm...

see more →

Clinicaltrials.gov  4 results

Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome
https://clinicaltrials.gov/ct2/show/NCT02921893

May 13th, 2022 - PRIMARY OBJECTIVE: I. Normalization of VEGF after 3 cycles of therapy. SECONDARY OBJECTIVES: I. Toxicity and safety of the combination of ixazomib citrate (ixazomib), lenalidomide, and dexamethasone. II. Hematologic response after 3 cycles of ther...

Treatment of POEMS Syndrome With Daratumumab
https://clinicaltrials.gov/ct2/show/NCT04396496

Aug 3rd, 2021 - This trial investigates the use of DARA, an antibody directed at the human CD38 molecule, for the treatment of patients with POEMS syndrome. This trial will enroll ten subjects, who will complete 12 four-week cycles of DARA, in combination with th...

POEMS Syndrome Treatment With Lenalidomide
https://clinicaltrials.gov/ct2/show/NCT01639898

Jul 5th, 2019 - The investigators propose to simultaneously set up two Phase II therapeutic trials: Trial "2 cycles" and trial "9 cycles" (Fleming plan in one stage). This will mean prospective multicentre studies, around a treatment with the lenalidomide-dexamet...

The Treatment of Lenalidomide in Patients With POEMS Syndrome
https://clinicaltrials.gov/ct2/show/NCT00971685

Sep 2nd, 2010 - Lenalidomide is a immunomodulatory drug derived from thalidomide, without neurotoxicity. Lenalidomide blocks the increased secretion of interleukin-6, tumor necrosis factor alpha and vascular endothelial growth factor (VEGF). The association with ...

see more →

News  4 results

FDA Grants Orphan Drug Designation to CFT7455 for Multiple Myeloma
https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-cft7455-for-multiple-myeloma

Aug 17th, 2021 - The FDA has granted an orphan drug designation to CFT7455, a MonoDAC degrader targeting IKZF1/3, for use as a potential therapeutic option in patients with multiple myeloma, according to an announcement from C4 Therapeutics, Inc.1 We are pleased ...

Ixazomib Frontline Triplet Misses PFS Endpoint in Transplant-Ineligible Myeloma
https://www.onclive.com/view/ixazomib-frontline-triplet-misses-pfs-endpoint-in-transplantineligible-myeloma

Dec 4th, 2020 - Christopher Arendt The triplet therapy of ixazomib (Ninlaro), lenalidomide (Revlimid), and dexamethasone showed an improvement in progression-free survival (PFS), but it was not statistically significant, compared with lenalidomide/dexamethasone ...

Spontaneous Recovery of Adrenal Insufficiency in POEMS Syndrome
https://www.medscape.com/viewarticle/586058

Jan 22nd, 2009 - Abstract POEMS syndrome is a rare multisystem disorder characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes. We report the first case of spontaneous recovery of adrenal insufficiency in a patient w...

POEMS Syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Multiple Myeloma and Skin Changes) With Cranial Vault Plasmocytoma and the Role of Surgery in Its Management
https://www.medscape.com/viewarticle/814257

Abstract and Introduction Abstract Introduction POEMS syndrome (an acronym of polyneuropathy, organomegaly, endocrinopathy, multiple myeloma and skin changes) is a paraneoplastic disorder related to an underlying plasma cell dyscrasia. The develop...

see more →